Evidence map›Paper›PMID 39917203›Full record

ArticleBioinformation2024

Molecular docking and simulation analysis of c-KIT and PDGFRα with phytochemicals as dual inhibitors for GIST.

Kaoutar El Khattabi, Sanaa Lemriss, Rachid El Jaoudi, Fouad Zouaidia

Abstract read
In one paragraph

Article in Bioinformation, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Lipopeptides fromBiotech (Basel (Switzerland)) · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Kaoutar El KhattabiMedical Biotechnology Laboratory, Rabat Medical and Pharmacy School, Mohammed V University in Rabat, Rabat, Morocco.
Sanaa LemrissDepartment of Biosecurity PCL3, Laboratory of Research and Medical Analysis of the Fraternal of Gendarmerie Royale, Rabat, Morocco.
Rachid El JaoudiMedical Biotechnology Laboratory, Rabat Medical and Pharmacy School, Mohammed V University in Rabat, Rabat, Morocco.
Fouad ZouaidiaMedical Biotechnology Laboratory, Rabat Medical and Pharmacy School, Mohammed V University in Rabat, Rabat, Morocco.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Mutations in the c-KIT or PDGFRα genes primarily drive gastrointestinal stromal tumors (GISTs). While tyrosine kinase inhibitors (TKIs) such as Imatinib have improved outcomes, resistance due to secondary mutations remains a significant challenge. This study used computational methods to identify phytochemicals from Moroccan plants as dual inhibitors of c-KIT and PDGFRα. Screening 545 phytochemicals, 6-Hydroxygenistein (6-OHG), a derivative of Genistein, showed high binding affinities (-10.3 kcal/mol for PDGFRα and -10.5 kcal/mol for c-KIT), comparable to Imatinib. 6-OHG demonstrated competitive binding affinities, favorable ADMET properties, good solubility, and oral bioavailability. Its antioxidant properties suggest a potentially lower toxicity profile. Interaction analysis revealed significant hydrogen bonds and hydrophobic interactions with key residues in both targets. Molecular dynamics simulations over 30 ns indicated stable complexes with consistent RMSD values, radius of gyration, solvent-accessible surface area, and hydrogen bonding patterns. Free binding energy calculations using the MM-PBSA method highlighted strong binding efficacy, with total binding energies of -278.0kcal/mol for PDGFRα and -202.1kcal/mol for c-KIT, surpassing Imatinib. These findings suggest that 6-OHG is a promising dual inhibitor for GIST therapy, potentially overcoming resistance mechanisms associated with current TKIs. However, further experimental validation is necessary to fully understand it's potential.

Indexed as

c-KITGISTmolecular dockingmolecular dynamicsmulti-drug targetPDGFRα

Identifiers

PMID39917203
PMCPMC11795502

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.